Literature DB >> 20110179

Thalassemia in Western Australia: 11 novel deletions characterized by Multiplex Ligation-dependent Probe Amplification.

Marion Phylipsen1, John F Prior, Erna Lim, Neela Lingam, Ingrid P Vogelaar, Piero C Giordano, Jill Finlayson, Cornelis L Harteveld.   

Abstract

The number of immigrants in Western Australia from many different areas where hemoglobinopathies are endemic has increased dramatically since the 1970s. Therefore, many different thalassemia mutations have been introduced in the country, which add a technological diagnostic problem to the serious burden of hemoglobinopathy management and to public health care. Recently, we have developed a rapid and simple technique based on Multiplex Ligation-dependent Probe Amplification to detect deletions causing alpha-and beta-thalassemia, deltabeta-thalassemia and Hereditary Persistence of Fetal Hemoglobin. A screening for (unknown) deletions was performed in a cohort of patients of different ethnic backgrounds preselected for their thalassemia phenotype, in which common deletions and point mutations were excluded. Out of 37 cases suspected to carry a deletion, 27 were found to carry 17 different deletion types of which 6 causing alpha-thalassemia and 5 causing beta-thalassemia were novel. For 3 of the deletions, we have been able to characterize the exact breakpoint sequences by long-range PCR and direct sequencing. These results show that MLPA is a suitable technology to detect unknown and uncommon deletions. These could represent a diagnostic problem when offering prevention to couples at risk presenting with unclear phenotypes and might result in a serious fetal problem when the deletion involves embryonic genes. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110179     DOI: 10.1016/j.bcmd.2009.12.011

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  The molecular basis of α-thalassemia.

Authors:  Douglas R Higgs
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

2.  Development and clinical implementation of a combination deletion PCR and multiplex ligation-dependent probe amplification assay for detecting deletions involving the human α-globin gene cluster.

Authors:  Benjamin R Kipp; Samantha E Roellinger; Patrick A Lundquist; W Edward Highsmith; D Brian Dawson
Journal:  J Mol Diagn       Date:  2011-06-25       Impact factor: 5.568

Review 3.  Disruption of long-range gene regulation in human genetic disease: a kaleidoscope of general principles, diverse mechanisms and unique phenotypic consequences.

Authors:  Shipra Bhatia; Dirk A Kleinjan
Journal:  Hum Genet       Date:  2014-02-05       Impact factor: 4.132

4.  Characterization of two novel Alu element-mediated α-globin gene cluster deletions causing α0-thalassemia by targeted next-generation sequencing.

Authors:  Zhiming Li; Xuan Shang; Shiqiang Luo; Fei Zhu; Xiaofeng Wei; Wanjun Zhou; Yuhua Ye; Tizhen Yan; Ren Cai; Xiangmin Xu
Journal:  Mol Genet Genomics       Date:  2020-01-02       Impact factor: 3.291

5.  Gap-PCR Screening for Common Large Deletional Mutations of β-Globin Gene Cluster Revealed a Higher Prevalence of the Turkish Inversion/Deletion (δβ)0 Mutation in Antalya.

Authors:  Türker Bilgen; Özden Altıok Clark; Zeynep Öztürk; M Akif Yeşilipek; İbrahim Keser
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

6.  Rare α0-thalassemia deletions detected by MLPA in five unrelated Brazilian patients.

Authors:  Natália O Mota; Elza M Kimura; Roberta D Ferreira; Gisele A Pedroso; Dulcinéia M Albuquerque; Daniela M Ribeiro; Magnun N N Santos; Cristina M Bittar; Fernando F Costa; Maria de Fatima Sonati
Journal:  Genet Mol Biol       Date:  2017-10-02       Impact factor: 1.771

7.  Breakpoint characterization of a rare alpha0 -thalassemia deletion using targeted locus amplification on genomic DNA.

Authors:  Quint P Hottentot; Emile de Meijer; Henk P J Buermans; Stefan J White; Cornelis L Harteveld
Journal:  Int J Lab Hematol       Date:  2021-07-12       Impact factor: 3.450

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.